Can quetiapine (Seroquel) or haloperidol (Haldol) cause akathisia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Seroquel or Haldol Cause Akathisia?

Yes, both quetiapine (Seroquel) and haloperidol (Haldol) can cause akathisia, but haloperidol carries a substantially higher risk. Haloperidol is associated with akathisia rates of approximately 33-57%, while quetiapine has a much lower incidence of 2.6-6%, comparable to placebo in many studies 1.

Risk Profile by Medication

Haloperidol (Haldol)

  • High akathisia risk: Haloperidol, as a typical (first-generation) antipsychotic, is strongly associated with extrapyramidal symptoms including akathisia 1.
  • Incidence rates: Studies demonstrate akathisia occurs in 33-57% of patients treated with haloperidol 2, 3.
  • Mechanism: As a potent D2 receptor antagonist, haloperidol has anticipated extrapyramidal symptoms that occur frequently 4.
  • Clinical significance: The American Family Physician guidelines note that typical antipsychotics like haloperidol should be avoided if possible due to significant extrapyramidal side effects 4.

Quetiapine (Seroquel)

  • Low akathisia risk: Quetiapine is considered an akathisia-sparing atypical antipsychotic 2.
  • Incidence rates: Akathisia occurs in only 2.6-6% of patients, similar to placebo rates (4.9-6.1%) 5, 3, 6.
  • FDA label data: The official Seroquel prescribing information confirms akathisia incidence of 4% in adults with schizophrenia/bipolar disorder, compared to 1% with placebo 7.
  • Comparative advantage: In head-to-head trials, quetiapine showed significantly lower akathisia rates than haloperidol (2.6% vs 36.8%) 8.

Clinical Presentation and Timing

Akathisia typically manifests as a subjective feeling of restlessness that generally occurs within the first few days of antipsychotic medication therapy 1.

Key features include:

  • Subjective inner restlessness and inability to remain still 1.
  • Onset usually within days of starting medication or after dose increases 1.
  • Can be severely distressing and associated with increased suicide risk, decreased medication adherence, and worsened agitation 9, 10.

Dose-Response Relationships

  • Haloperidol: Higher doses carry greater or equal akathisia risk with a monotonic or hyperbolic dose-response curve 6.
  • Quetiapine: Demonstrates a flat dose-response curve with negligible akathisia risk across examined doses (up to 800 mg/day) 6.

Management Considerations

If akathisia develops, the first-line approach is dose reduction or switching to an akathisia-sparing antipsychotic like quetiapine or olanzapine 1, 11.

Alternative management strategies include:

  • Propranolol: 10-30 mg two to three times daily as adjunctive treatment 11, 9.
  • Vitamin B6: 600-1200 mg/day for ≥5 days showed significant efficacy 9.
  • Mirtazapine: 15 mg/day demonstrated the greatest efficacy in network meta-analysis 9.
  • Avoid adding anticholinergics like benztropine or trihexyphenidyl in elderly patients with typical antipsychotics 4.

Important Caveats

  • While quetiapine generally has low akathisia risk, case reports document that it can still cause akathisia, especially in patients prone to extrapyramidal symptoms 12.
  • The association between akathisia and suicidality is particularly concerning in male patients 10.
  • Akathisia may be confused with agitation or worsening psychosis, leading to inappropriate dose escalation rather than reduction 10.

References

Research

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2005

Research

Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.